When it comes to CRC treatment, TF-binding peptide (TBP-Ps) functionalized polymers can selectively and stably bind to TF and deliver doxorubicin (DOX) to TfR-overexpressing HCT-116 cells (50), providing an alluring strategy in formulating TF-targeted nanomedicines. The gene discussed is TFRC; the disease is colorectal carcinoma.